BACKGROUND: The objective of this study was to investigate serum levels of immunosuppressive cytokines TGF beta 1 and VEGF and count of immune cells in peripheral blood in stage II and III colorectal cancer patients. METHODS: Blood samples were collected from 22 colorectal patients and 25 healthy controls before the start of treatment. All patients were examined by a clinical immunologist to exclude patients with immune disorders and autoimmune diseases. TGF beta 1 and VEGF were measured by ELISA, and anti-tumor cellular immunity cells (CD4, CD8, B cells, NK cells) were measured by flow cytometry. RESULTS: TGF beta 1 and VEGF plasma levels were significantly increased in stage II and III colorectal patients compared with control group (both p < 0.0001). A decrease in the cellular immunity was shown in the absolute numbers of cytotoxic T lymphocytes (CD8+ ; p = 0.0240), helper T lymphocytes (CD4+ ; p = 0.0019), and natural killer cells (CD16 + CD56+; p < 0.0001) in both stage II and stage III patients. On the contrary, B lymphocyte (CD19+) serum levels were increased in colon cancer patients (p < 0.0001) compared to the control group. CONCLUSIONS: Our results show peripheral blood levels of TGF beta and VEGF were significantly increased in colorectal patients and changes in cellular anticancer immunity in comparison to control group. These results will be compared with results from Immunoscore.
- Klíčová slova
- CD3+ lymphocytes, CD8+ lymphocytes, TGF-beta, VEGF, colorectal cancer,
- MeSH
- adenokarcinom imunologie MeSH
- B-lymfocyty imunologie MeSH
- buněčná imunita MeSH
- buňky NK imunologie MeSH
- CD4-pozitivní T-lymfocyty imunologie MeSH
- CD8-pozitivní T-lymfocyty imunologie MeSH
- kolorektální nádory imunologie MeSH
- krevní oběh MeSH
- lidé středního věku MeSH
- lidé MeSH
- počet lymfocytů MeSH
- staging nádorů MeSH
- transformující růstový faktor beta1 krev MeSH
- vaskulární endoteliální růstový faktor A krev MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- transformující růstový faktor beta1 MeSH
- vaskulární endoteliální růstový faktor A MeSH
BACKGROUND: Trastuzumab (Herceptin® - H) has been the standard-of-care for patients with HER2+ breast cancer (BC) since 2009 in the Czech Republic. Neoadjuvant application of H increases the number of patients who achieve pathological complete remission (pCR) and improves patients' outcomes. AIM: This study aimed to assess the effect of neoadjuvant therapy (NAT) with H in patients with early HER2+ BC and to correlate the therapeutic outcome with overall survival (OS). We defined pCR as no invasive carcinoma (ypT0) or in situ residual carcinoma (ypTis) in breast tissue and no invasive carcinoma in axillary lymphatic nodes (ypN0). To correlate pCR with the hormone dependency of BC, we compared the number of patients who achieved pCR between those with hormone-dependent (estrogen receptor (ER) +) BC and those with hormone-negative (ER-) BC. RESULTS: We evaluated data from 148 patients with HER2+ BC, most of whom were at stage II. Of these, 50.7% were premenopausal women and 45.9% had ER- BC. Most patients were treated with anthracyclines followed by taxanes and H. pCR was reported in 50% of patients (74/148). ER+ BC regressed more often to ypTis stage (24/35), ER- BC to ypT0ypN0 stage (26/39). The 1-year OS rate of patients who achieved pCR was significantly higher than that of patients who did not (100.0% vs. 95.3%, p = 0.009). Median OS was not achieved in pCR patients group. CONCLUSION: Patients who achieved pCR had a better prognosis than patients who did not. Key words: neoadjuvant therapy - trastuzumab - early breast cancer - pathological complete remission - prognosis The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers. Submitted: 14. 9. 2017 Accepted: 15. 2. 2018.
- MeSH
- antracykliny terapeutické užití MeSH
- lidé MeSH
- nádory prsu farmakoterapie patologie MeSH
- neoadjuvantní terapie MeSH
- onkologická péče - zařízení MeSH
- prognóza MeSH
- protinádorové látky imunologicky aktivní terapeutické užití MeSH
- receptor erbB-2 * MeSH
- taxoidy terapeutické užití MeSH
- trastuzumab terapeutické užití MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
- Názvy látek
- antracykliny MeSH
- ERBB2 protein, human MeSH Prohlížeč
- protinádorové látky imunologicky aktivní MeSH
- receptor erbB-2 * MeSH
- taxoidy MeSH
- trastuzumab MeSH
